Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
SUMMARY Identification of unique leads represents a significant challenge in drug discovery. This hurdle is magnified in neglected diseases such as tuberculosis. We have leveraged public high-throughput screening (HTS) data, to experimentally validate virtual screening approach employing Bayesian models built with bioactivity information (single-event model) as well as bioactivity and cytotoxicity information (dual-event model). We virtually screen a commercial library and experimentally confirm actives with hit rates exceeding typical HTS results by 1-2 orders of magnitude. The first dual-event Bayesian model identified compounds with antitubercular whole-cell activity and low mammalian cell cytotoxicity from a published set of antimalarials. The most potent hit exhibits the in vitro activity and in vitro/in vivo safety profile of a drug lead. These Bayesian models offer significant economies in time and cost to drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 2×
“Finding new hits is, therefore, greatly enhanced over current screening methods as typical experimental HTS success rates are less than 1% (Payne et al., 2007) and for Mtb growth inhibition screens they are similar (Ananthan et al., 2009, Gold et al., 2012, Maddry et al., 2009, Magnet et al., 2010,…”
BackgroundA Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Fortunately, one screen of the non-pathogenic Mycobacterium smegmatis unearthed a diarylquinoline hit that led to the clinical candidate bedaquiline (Andries et al., 2005), while another resulted in the early-phase candidate SQ109 (Lee et al., 2003).”
BackgroundCollins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Impact of high-throughput screening in biomedical research
Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3368 · Cited by 1,364 · cited 1×
“…whole-cell high-throughput screens (HTS) of commercial libraries have searched for inhibitors of mycobacterial growth, at a cost of millions of dollars, with resultant low single-digit (or less) hit rates (Macarron et al., 2011, Magnet et al., 2010, Mak et al., 2012, Stanley et al., 2012).”
BackgroundWhy Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417 · cited 1×
“Toxicity-related events lead to more than one-third of all clinical trial failures and 90% of the withdrawals of approved drugs (Schuster et al., 2005).”
BackgroundDifferential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates
Xie, Z., Siddiqi, N., & Rubin, E. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4778-4780.2005 · Cited by 136 · cited 1×
“Following a literature protocol (Xie et al., 2005), M. tuberculosis H37Rv grown to the exponential phase (A 600 =0.5) was adjusted to 5 × 10 5 CFU/mL in 2 mL of Middlebrook 7H9 medium supplemented with 10% ADS, 0.25% glycerol and 0.5% Tween 80.”
MethodInfluential
Cited by
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578
Self-citationVatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Korotcov, A., Tkachenko, V., Russo, D. P., & Ekins, S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00578 · Cited by 352
Self-citationEvolution of Support Vector Machine and Regression Modeling in Chemoinformatics and Drug Discovery
Rodríguez-Pérez, R., & Bajorath, J. (2022) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-022-00442-9 · Cited by 259
Metadata
- Authors
- Ekins, S., Reynolds, R. C., Kim, H., Koo, M.-S., Ekonomidis, M., Talaue, M., Paget, S. D., Woolhiser, L. K., Lenaerts, A. J., Bunin, B. A., Connell, N., & Freundlich, J. S.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 20
- Issue
- 3
- Pages
- 370-378
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2046613566
- Cited by
- 97
- References
- 6
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery. https://app.cochat.ai/papers/10.1016/j.chembiol.2013.01.011
- The paper
- Ekins, S., Reynolds, R. C., Kim, H., Koo, M.-S., Ekonomidis, M., Talaue, M., Paget, S. D., Woolhiser, L. K., Lenaerts, A. J., Bunin, B. A., Connell, N., & Freundlich, J. S. (2013). Bayesian Models Leveraging Bioactivity and Cytotoxicity Information for Drug Discovery. Chemistry & Biology. https://doi.org/10.1016/j.chembiol.2013.01.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.